Core Viewpoint - BioAge Labs, Inc. announced a proposed underwritten public offering to sell up to $75 million of its common stock, with an additional option for underwriters to purchase up to $11.25 million more, aimed at funding various corporate activities [1][3]. Group 1: Offering Details - The proposed offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. - The shares are being offered under a registration statement that became effective on November 25, 2025 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for research, clinical development, manufacturing of product candidates, working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].
BioAge Announces Proposed Public Offering